Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma

A method for non-therapeutically inhibiting a key transcriptional regulatory factor of malignant melanoma MITF in vitro, which comprises a step of:

• contacting MITF with a compound of formula A, or an optical isomer, or a racemate, or a solvate or a pharmaceutically acceptable salt thereof, thereby inhibiting activity of MITF,
• wherein,
• Ar is phenyl, pyridyl, pyrimidinyl, or aromatic ring without or containing nitrogen, sulfur, oxygen heteroatom;
• X1 and X2 are each independently selected from the group consisting of 0 atom, S atom, substituted or unsubstituted N atom, and C atom;
• wherein the term “substituted” refers to having one or more substituents selected from the group consisting of halogen, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, furan, and substituted or unsubstituted 5-7 membered heterocyclic ring containing O or S heteroatom;
• wherein the substituted heterocyclic ring contains 1-3 substituents selected from the group consisting of substituted or unsubstituted phenyl, C1-C3 alkyl, C1-C3 haloalkyl, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, halogen, and benzyl;
• R1 and R2 are each independently selected from the group consisting of halogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 alkoxy, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, and substituted or unsubstituted C3-C8 cycloalkyl;
• wherein the “substituted” refers to having one or more substituents selected from the group consisting of halogen, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, furan, and substituted or unsubstituted 5-7 membered heterocyclic ring containing O or S heteroatom;
• wherein the substituted heterocyclic ring contains 1-3 substituents selected from the group consisting of substituted or unsubstituted phenyl, C1-C3 alkyl, C1-C3 haloalkyl, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, halogen, and benzyl.

A method for inhibiting melanin formation or for whitening skin, which comprises a step of:

• administering a compound of formula A, or an optical isomer, or a racemate, or a solvate or a pharmaceutically acceptable salt thereof to a subject in need thereof,
• wherein,
• Ar is phenyl, pyridyl, pyrimidinyl, or aromatic ring without or containing nitrogen, sulfur, oxygen heteroatom;
• X1 and X2 are each independently selected from the group consisting of O atom, S atom, substituted or unsubstituted N atom, and C atom;
• wherein the term “substituted” refers to having one or more substituents selected from the group consisting of halogen, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, furan, and substituted or unsubstituted 5-7 membered heterocyclic ring containing O or S heteroatom;
• wherein the substituted heterocyclic ring contains 1-3 substituents selected from the group consisting of substituted or unsubstituted phenyl, C1-C3 alkyl, C1-C3 haloalkyl, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, halogen, and benzyl;
• R1 and R2 are each independently selected from the group consisting of halogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 alkoxy, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, and substituted or unsubstituted C3-C8 cycloalkyl;
• wherein the “substituted” refers to having one or more substituents selected from the group consisting of halogen, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, furan, and substituted or unsubstituted 5-7 membered heterocyclic ring containing O or S heteroatom;
• wherein the substituted heterocyclic ring contains 1-3 substituents selected from the group consisting of substituted or unsubstituted phenyl, C1-C3 alkyl, C1-C3 haloalkyl, −OH, −NH2, −CN, −NH (C1-C3 alkyl), −N (C1-C3 alkyl)2, halogen, and benzyl.